Molina Healthcare

After several years of elevated utilization that has not been fully offset by rate increases yet, covered MCO shares have risen about 35% on average since our last managed care industry report in September 2025, in anticipation of rising profits in at-risk medical insurance plans.

Why it matters: While trading much closer to fair value than they were about a year ago, the managed care organizations we cover still look moderately undervalued to fairly valued to us, with plenty of upside in their earnings growth prospects for the foreseeable future relative to norms. On average through 2030, we expect covered MCOs to grow earnings per share in the midteens compounded annually versus the typical industry goal of low-double-digit growth. This accelerated earnings growth looks likely due to potential margin improvement in at-risk plans—including Medicare Advantage (seniors), the individual exchanges, and Medicaid (low-income)—as the MCOs raise rates, adjust plan designs, and exit unprofitable geographies.

The bottom line: We continue to see reasonably valued to moderately undervalued shares in the managed care industry, even when considering their High to Very High Uncertainty Ratings, which remain about a notch above historical ratings due primarily to elevated regulatory uncertainty. New policy changes are threatening the individual exchange (2026) and Medicaid (2027) businesses. The market appears to be discounting companies with significant exposure to these businesses—like Centene, Elevance, and Molina—relative to their intrinsic value, which is creating an opportunity for long-term investors, in our view. Regulatory actions related to Medicare Advantage and vertical integration in the industry also remain possible. Cigna, CVS, Humana, and UnitedHealth appear most exposed and could eventually face potential fines and even forced separations in some scenarios.

BLANK PAGEFor more details on how each MCO stacks up against its peers, along with the industry's growth prospects, moat ratings, moat sources, and regulatory concerns, please see our September 2026 Industry Landscape on managed care organizations.

We keep our fair value estimate at $262 per share.

Including another major decline in profits in 2026 with limited upside in 2027, we suspect Molina will work diligently to boost its margins in the long run, including exits of unprofitable business lines like its non-Medicaid-related Medicare Advantage product in 2027. From under 1% expected in 2026, we expect the firm to work toward reaching its previous pretax margin target of 4%-5% over time, although our fair value estimate only depends on that margin topping out in the mid-3s in the second half of our explicit 10-year forecast period.

Beyond 2025, Molina appears likely to face both headwinds and tailwinds in its businesses. On the regulatory front, we see the potential for headwinds in all three of its major business lines: Medicaid, the individual exchanges, and Medicare. Those concerns could reduce membership and constrain margins in Medicaid and the individual exchanges in 2026-27 and reduce long-term margins in Medicare. We have incorporated lower membership levels and lower-than-targeted margins in Medicaid and the individual exchanges in the intermediate term and lower margins in Medicare than targeted in the long run due to these concerns.

However, even our expectations for lower-than-targeted margins in the intermediate and long term are higher than where Molina currently operates, which should eventually create some tailwinds for the organization. The mismatched rates and medical utilization experienced by most industry players since late 2023 appear uniquely imbalanced, and this mismatch looks remediable over time through rate increases, plan design changes, and plan exits. We expect Molina's margins will increase materially from recent troughs, including a pretax margin increase from less than 1% in 2026 to over 2% by 2030 and to the mid-3s by 2035. In the long run, those margin tailwinds should more than offset the expected headwinds on the bottom line based on our projections.

We give Molina a Narrow Morningstar Economic Moat Rating, although the near-term quantitative story appears weak due to ongoing challenges with rates not keeping up with elevated medical utilization, combined with regulatory headwinds in its top two businesses: Medicaid and the individual exchanges.

Qualitatively, we see the strongest competitive advantages in its Medicaid business, where the company appears to enjoy both cost advantages relative to peers and customer switching costs associated with contracts in that end market. Beyond Medicaid, we see its other major plans—in Medicare and on the individual exchanges—primarily as complementary to its Medicaid business rather than boasting their own moats.

Medicaid Market Under Pressure Due to Mismatched Rates/Utilization and Regulatory Scrutiny

Molina is a midtier but growing provider of Medicaid’s managed care plans, which primarily serve low-income individuals. We estimate that over half of Molina’s profits are typically generated from its Medicaid business, making that business the primary determinant of its moat rating and sources. Historically, we have thought that successful Medicaid businesses have the potential to benefit from two moat sources—cost advantages and customer switching costs—and we see those moat sources at Molina in Medicaid.

Cost Advantage

Molina's significant scale, efficient operations, and effective programs to manage the Medicaid population have helped the firm offer plans that are more attractive financially and qualitatively to state partners than other private health insurers, which contributes to its expanding market share. Molina’s intense focus on cost management has created a cost advantage for the insurer that state partners continue to recognize, and as evidence of that advantage, Molina typically boasts better medical cost ratios (costs over premiums) in Medicaid than most of its peers. That cost advantage helps the firm with two major factors: (1) winning business in Medicaid, as state partners can benefit from the cost savings Molina generates, and (2) maintaining profitability better than similar MCOs during challenging times, which we are still seeing evidence of now.

While the current mismatch in rates and utilization is cutting into industry profits, Molina investors should realize that states are subject to an actuarial soundness requirement in Medicaid, which means they must lift rates to meet utilization trends, which suggests that a rising tide may lift all boats in the Medicaid market eventually, as utilization trends that states use to determine Medicaid rates should start lapping surging levels over time.

Customer Switching Costs

Beyond Molina’s cost advantages in Medicaid, the Medicaid market has the potential to create switching costs through contractual obligations and entrenched relationships, and the strength of those switching costs makes the Medicaid business relatively unique in the health insurance industry. For example, employers typically only contract with a medical insurer for one year. In contrast, while contract terms vary by state, initial Medicaid contract lengths with managed care companies typically last three to five years. Additional renewal periods can lengthen those initial contract periods by several years as well, meaning contracts from one request for proposal cycle often extend beyond five years. Even after these contractually stipulated arrangements, the relationships between a state and its managed care plan providers can last much longer than one request for proposal cycle. For example, Molina has highlighted that its contractual renewal rate stands around 90%, and on average, the length of Molina’s relationships with state Medicaid clients appears longer than the 10-year narrow-moat threshold, by our calculations.

Other End Markets: Margins Are Currently Challenged

While we see positive characteristics in Molina’s other major businesses—the individual exchanges and Medicare—we do not believe Molina has dug an economic moat in them. Positively, both businesses typically enjoy higher gross margins than the firm’s Medicaid business, which should help the company generate economic profits in the long run, although we recognize the current margin challenges in each. Also, Molina sticks to its knitting from a demographic perspective in these businesses by targeting lower-income individuals, which we believe can help it meet the needs of those specific populations in their journeys across income and age spectrums. Overall, though, we do not believe these businesses will be value-destructive in the long run and appreciate that they look complementary to Molina’s Medicaid offerings. These plans may even be value-additive due to the typically higher margins, but we do not believe Molina benefits from any major structural advantages in either, especially compared with its MCO peers in those end markets.

Regulatory Concerns: Looming Declines in Medicaid and Individual Plans May Constrain Profits

Our moat analysis for Molina includes potential changes to the US healthcare system, which currently appear focused on the company's key end markets: Medicaid and the individual exchanges. We think Republican policy changes may constrain the company’s profits through 2027 for a few reasons, despite significant margin upside potential from current trough levels. First, federal subsidies for individual exchange plans expired at the end of 2025, which significantly reduced the affordability of plans on the exchanges and is cutting into that population. Given the typically higher margins in that business for Molina, those lost subsidies could extend the pain already being felt in that market through 2026. Second, the 2025 domestic tax and spending act aims to reduce Medicaid spending through work requirements, administrative hurdles, and other factors. Membership cuts and potential mix shifts in Molina’s core market could constrain its profit outlook through 2027.

Molina could become an acquisition target for one of the larger MCOs that want more exposure to government-sponsored programs.

Molina's end markets appear countercyclical (Medicaid and the individual exchanges) or at least recession-resistant (Medicare), which could make it a good relative pick in economic downturns.

States have increasingly outsourced Medicaid programs to MCOs like Molina because they help reduce the uncertainty that comes from fluctuating utilization patterns and medical cost inflation, while also helping beneficiaries consume healthcare more efficiently.

Molina continues to face more competition, as its Medicaid peers and large commercial insurers aim to expand into new states and new populations.

Molina turned in weak earnings in 2025, as medical utilization surged without a proportionate increase in rates, which has exposed some of the concerns that Molina faces as a medical insurer focused on at-risk relationships.

Over half of Molina's membership comes from just four Medicaid states. The loss of any of these large contracts would hurt financially.